Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Poolbeg Pharma Ltd. ( (GB:POLB) ).
Poolbeg Pharma announced that its Executive Chair, Cathal Friel, participated in a recent fundraising event, acquiring 4,000,000 new ordinary shares at 2.5p per share. This transaction increases Friel’s total holdings to approximately 5.91% of the company’s issued share capital, potentially strengthening his influence within the company and signaling confidence in its strategic direction.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. The company’s clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome and metabolic conditions such as obesity, with the development of an oral encapsulated GLP-1.
Average Trading Volume: 2,034,040
Technical Sentiment Signal: Sell
See more insights into POLB stock on TipRanks’ Stock Analysis page.